Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03620578
Title DA-EPOCH-R Induction Followed by Nivolumab Consolidation in Newly Diagnosed MYC, BCL2 and/or BCL6 Rearranged HGBL (HO152)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Stichting Hemato-Oncologie voor Volwassenen Nederland
Indications

B-cell lymphoma

Therapies

Cyclophosphamide + Doxorubicin + Etoposide + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate

Age Groups: senior | adult
Covered Countries BEL


No variant requirements are available.